Zöliakie oder glutensensitive Enteropathie und hereditäre Speichererkrankungen

Bekannte häufige Ursachen einer hepatischen Steatose sind Insulinresistenz auf dem Boden eines metabolischen Syndroms und Alkohol, die zur nicht alkoholischen (NAFLD) oder zur alkoholischen Fettlebererkrankung (AFL) führen, sowie akute und chronische Virusinfektionen. Zusätzlich können aber auch die Zöliakie und hereditäre Speichererkrankungen die Entwicklung einer Fettleber provozieren; progediente Formen umfassen die Steatohepatitis und Zirrhose. In allen diesen Fällen empfiehlt sich hinsichtlich möglicher Komplikationen, Risiken und Komorbiditäten eine frühzeitige Diagnosestellung.

Schlüsselwörter

Zöliakie - Morbus Wilson - Morbus Gaucher - Morbus Niemann-Pick - lysosomale saure Lipase-Defizienz

• Literatur

• 1 Kälsch J, Bechmann LP, Manka P. et al. Non-alcoholic steatohepatitis occurs in celiac disease and is associated with cellular stress. Z Gastroenterol 2013; 51: 26-31
• 2 Petersen J, Ciacchi L, Tran MT. et al. T cell receptor cross-reactivity between gliadin and bacterial peptides in celiac disease. Nat Struct Mol Biol 2020; 27: 49-61
• 3 Gómez-Rial J, Rivero-Calle I, Salas A. et al. Rotavirus and autoimmunity. J Infect 2020; 81: 183-189
• 4 Tovo PA, Opramolla A, Pizzol A. et al. Overexpression of endogenous retroviruses in children with celiac disease. Eur J Pediatr 2021; 180: 2429-2434
• 5 Al-Toma A, Volta U, Auricchio R. et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United European Gastroenterol J 2019; 7: 583-613
• 6 Mårild K, Stephansson O, Grahnquist L. et al. Down syndrome is associated with elevated risk of celiac disease: a nationwide case-control study. J Pediatr 2013; 163: 237-242
• 7 Husby S, Koletzko S, Korponay-Szabó IR. et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012; 54: 136
• 8 Schuppan D, Junker Y, Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009; 137: 1912-1933
• 9 Stremmel W, Meyerrose KW, Niederau C. et al. Wilson disease: clinical presentation, treatment, and survival. Ann Intern Med 1991; 115: 720-726
• 10 Giagheddu A, Demelia L, Puggioni G. et al. Epidemiologic study of hepatolenticular degeneration (Wilsonʼs disease) in Sardinia (1902–1983). Acta Neurol Scand 1985; 72: 43-55
• 11 Becker M, Rohrschneider K. Ocular manifestations of Wilson disease. Ophthalmol Z Dtsch Ophthalmol Ges 1997; 94: 865-870
• 12 Mehta A. Epidemiology and natural history of Gaucherʼs disease. Eur J Intern Med 2006; 17 (Suppl.) S2-S5
• 13 Starosta R, Dornelles AD, Vairo FP. et al. Liver disease in a cohort of patients with Gaucher disease from Southern Brazil: a cross-sectional study. J Hepatol 2018; 68: S632-S633
• 14 Revel-Vilk S, Szer J, Mehta A. et al. How we manage Gaucher Disease in the era of choices. Br J Haematol 2018; 182: 467-480
• 15 Kaplan P, Baris H, De Meirleir L. et al. Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr 2013; 172: 447-458
• 16 Mistry PK, Lukina E, Ben Turkia H. et al. Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: the phase 3 ENGAGE trial. Am J Hematol 2017; 92: 1170-1176
• 17 Schiffmann R, FitzGibbon EJ, Harris C. et al. Randomized, controlled trial of miglustat in Gaucherʼs disease type 3. Ann Neurol 2008; 64: 514-522
• 18 Schuchman EH, Desnick RJ. Types A and B Niemann-Pick disease. Mol Genet Metab 2017; 120: 27-33
• 19 Vanier MT. Niemann-Pick diseases. Handb Clin Neurol 2013; 113: 1717-1721
• 20 McGovern MM, Avetisyan R, Sanson BJ. et al. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). Orphanet J Rare Dis 2017; 12: 41
• 21 Patterson MC, Hendriksz CJ, Walterfang M. et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab 2012; 106: 330-344
• 22 Patterson MC, Mengel E, Wijburg FA. et al. Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet J Rare Dis 2013; 8: 12
• 23 Rader DJ. Lysosomal acid lipase deficiency – a new therapy for a genetic lipid disease. N Engl J Med 2015; 373: 1071-1073
• 24 Burton BK, Deegan PB, Enns GM. et al. Clinical Features of Lysosomal Acid Lipase Deficiency. J Pediatr Gastroenterol Nutr 2015; 61: 619-625
• 25 Reiner Ž, Guardamagna O, Nair D. et al. Lysosomal acid lipase deficiency – an under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis 2014; 235: 21-30
• 26 Lohse P, Maas S, Lohse P. et al. Compound heterozygosity for a Wolman mutation is frequent among patients with cholesteryl ester storage disease. J Lipid Res 2000; 41: 23-31
• 27 Muntoni S, Wiebusch H, Jansen-Rust M. et al. Prevalence of cholesteryl ester storage disease. Arterioscler Thromb Vasc Biol 2007; 27: 1866-1868
• 28 Canbay A, Müller MN, Philippou S. et al. Cholesteryl ester storage disease: fatal outcome without causal therapy in a female patient with the preventable sequelae of progressive liver disease after many years of mild symptoms. Am J Case Rep 2018; 19: 577-581
• 29 Su K, Donaldson E, Sharma R. Novel treatment options for lysosomal acid lipase deficiency: critical appraisal of sebelipase alfa. Appl Clin Genet 2016; 9: 157-167
• 30 Bernstein DL, Hülkova H, Bialer MG. et al. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol 2013; 58: 1230-1243
• 31 Jones SA, Valayannopoulos V, Schneider E. et al. Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants. Genet Med Off J Am Coll Med Genet 2016; 18: 452-458
• 32 Burton BK, Balwani M, Feillet F. et al. A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. N Engl J Med 2015; 373: 1010-1020
• 33 Canbay A, Gerken G, Bechmann LP. Hepatische Steatosen: Differenzialdiagnostik und aktuelle Aspekte. Internist 2016; 57: 879-892